Ask AI
ProCE Banner Series

Optimal Therapeutic Sequencing in Relapsed/Refractory CLL: Pharmacist Perspectives

Join us for this case-based, interactive, ACPE-certified live webinar featuring expert perspectives for pharmacists on treatment for patients with relapsed/refractory CLL. Be sure to bring your questions for the live question and answer session with the expert panel.

Who Should Attend

This program is intended for pharmacists and other healthcare professionals globally who care for patients with chronic lymphocytic leukemia.

Topics

Hematologic malignancies

Leukemias

Lymphomas

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners' knowledge, competence, and performance to optimize clinical outcomes for patients with chronic lymphocytic leukemia. 

Target Audience
This program is intended for pharmacists and other healthcare professionals globally who care for patients with chronic lymphocytic leukemia. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Integrate new and emerging data on non-covalent BTK inhibitors into the management of patients with relapsed/refractory CLL/SLL
  • Plan therapeutic strategies for patients with relapsed/refractory CLL/SLL based on current guidelines, available clinical evidence, and expert recommendations
  • Proactively select and sequence treatment regimens and long-term treatment plans for individual patients with CLL/SLL to optimize clinical benefit
  • Assess patients with relapsed/refractory CLL/SLL who have progressed on or following covalent BTK inhibitor therapy for resistance mutations
  • Implement effective interprofessional team processes and workflows to promote adherence to and persistence with oral anticancer therapy to ensure optimal clinical outcomes in patients with relapsed/refractory CLL/SLL
  • Mitigate and manage treatment-related and disease-related adverse events in patients with relapsed/refractory CLL/SLL

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-219-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Lilly.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191